非小細(xì)胞肺癌（NSCLC）是惡化程度高、治療難度大的肺部癌癥，其發(fā)生常與多種相關(guān)基因靶點(diǎn)突變或通路異常有關(guān)，如表皮生長(zhǎng)因子受體突變、間變性淋巴瘤激酶重排等。靶向藥物的出現(xiàn)為NSCLC治療提供了新方向，吉非替尼、厄洛替尼、奧希替尼、勞拉替尼及多靶點(diǎn)抑制劑為常見的靶向治療藥，臨床試驗(yàn)結(jié)果也顯示出一定的療效。對(duì)近年來國(guó)內(nèi)外有關(guān)NSCLC相關(guān)靶向治療藥物中的部分值得引起注意的臨床試驗(yàn)研究結(jié)果進(jìn)行綜述，以期為制定相關(guān)的臨床用藥方案提供依據(jù)。

Non-small cell lung cancer (NSCLC) is a kind of high-deterioration as well as difficult-to-treat cancer, which is commonly associated with a variety kinds of targets' mutations and abnormal pathways, such as epidermal growth factor receptor, anaplasticlymphoma kinase, et al. The emergence of target therapies provides novel orientations for the treatments of NSCLC patients. Recently, several clinical trials show, to some extent, extraordinary efficacy, like gefitinib, erlotinib, osimertinib, lorlatinib, some multi-target inhibitors and so on. This article reviews some results of several trials at home and abroad which could give more evidence, so as to support doctors in designing a more effective clinical therapy for the patients.

R944.5

國(guó)家自然科學(xué)基金青年科學(xué)基金資助項(xiàng)目（81302841）；遼寧省高等學(xué)校優(yōu)秀人才支持計(jì)劃資助項(xiàng)目（LJQ2014086）